In 110 patients with dMMR/MSI-H locally advanced colorectal cancer, adding celecoxib to neoadjuvant toripalimab raised pathological complete response to 89% vs 69% with toripalimab alone (difference 19 points; p=0·014), with similar grade 3 toxicity (5% vs 7%).
RCTn = 110
Hu et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial